Skip to main content
NRXP logo

NRXP · NRX Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track NRXP — free
$2.54 -0.01 (-0.39%) Play latest call Q3 2026 earnings call transcript
Market Cap
$113.04M
Shares
44.33M
Volume · Nov 19 1.4M Avg daily vol (3M) 1.06M

NRX Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for NRX Pharmaceuticals, Inc. (NRXP), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-17
NRX Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call Transcript
Confident tone
Revenue
$1.16M
▲ 378.9% YoY
Gross margin
24.6%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-10-30
NRX Pharmaceuticals, Inc. (NRXP) October 30, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
NRX Pharmaceuticals, Inc. (NRXP) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-17
NRX Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
Confident tone ALS program (GinEuro / GNK-301) SPARC-TMS trial with DARPA/military Preservative-free ketamine ANDA progress
Revenue
$1.10M
Gross margin
38.7%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-18
NRX Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
Confident tone NRX-101 and MIND-1 Trial NRX-100 NDA and Regulatory Pathway Ketafree / Preservative-Free Ketamine Approval
Revenue
$1.07M
Gross margin
40.9%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
NRX Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript
Confident tone FDA engagement and regulatory designations NRX100 NDA and real-world evidence pathway Hope Therapeutics subsidiary and clinic network
Revenue
$983,000*
Gross margin
58.5%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-17
NRX Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript
Positive tone ONE-D protocol / TMS + DCS HOPE Therapeutics clinic network Manufacturing and supply (Blow-Fill-Seal)
Revenue
$242,000
Gross margin
59.9%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-20
NRX Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript
Confident tone NRX100 ketamine regulatory progress Hope Therapeutics clinic subsidiary Balance sheet and financing
Revenue
$0
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-31
NRX Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
Confident tone NRX-100 NDA and regulatory progress NRX-101 oral combination for suicidality HOPE Therapeutics clinic network
Revenue
$0
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-17
NRX Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript
Confident tone HOPE Therapeutics Clinic Roll-Up NRX-101 Bipolar Depression NRX-100 Preservative-Free Ketamine NDA
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-15
NRX Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript
Confident tone NRX-101 oral treatment for suicidal bipolar depression Suicidality public health mission Hope Therapeutics clinic acquisitions
Revenue
$0
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
NRX Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
Confident tone NDA filings for NRX-100 and NRX-101 NRX-101 differentiation on safety (akathisia/suicidality) HOPE Therapeutics clinic roll-up
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-16
NRX Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
Confident tone NRX-101 in bipolar depression / akathisia HTX-100 (IV ketamine) for suicidal depression Regulatory and FDA pathway
Diluted EPS
$-0.74
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-04-02
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
Confident tone Hope Therapeutics and IV ketamine NRX-101 bipolar depression trial and Alvogen partnership Chronic pain and PTSD indications
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
NRX Pharmaceuticals, Inc. (NRXP) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.70
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q2 2023 Earnings Call Transcript
Diluted EPS
$-1.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q1 2023 Earnings Call Transcript
Diluted EPS
$-1.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
NRX Pharmaceuticals, Inc. (NRXP) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
NRX Pharmaceuticals, Inc. (NRXP) Q3 2022 Earnings Call Transcript
Diluted EPS
$-1.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q2 2022 Earnings Call Transcript
Diluted EPS
$-1.10
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q1 2022 Earnings Call Transcript
Diluted EPS
$-2.10
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q3 2021 Earnings Call Transcript
Diluted EPS
$-7.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Date not confirmed
NRX Pharmaceuticals, Inc. (NRXP) Q2 2021 Earnings Call Transcript
Diluted EPS
$-4.10
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 webcasts
Key facts CIK 1719406 CUSIP 629444209 13F (30d) 53 filings 49 filers Visit website Investor relations